Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by StockHawk1on Mar 24, 2023 7:22pm
161 Views
Post# 35359765

AGN's DMT studies

AGN's DMT studies

The phara-development company Algernon Pharmaceuticals (AGN.c AGNPF) is helping to pave the way in psychdelic medicine by studying if DMT can help patients with brain injuries. The company is doing this through 2 studies.


This first study (which is currently ongoing) has the goal of determining if DMT can help post-stroke patients. AGN is currently dosing healthy patients to define a safe and non-psychedelic dose of DMT. In the next phase of this study, AGN will give the determined safe dose to stroke survivors to study if/how it improves their brain health. 


AGN has also planned a similar study which will examine if DMT can aid those with Traumatic Brain Injuries (TBI). The company is hoping to use data from its stroke study (such as the determined safe DMT dose) to expidite this study. 


For more information, you can check out AGN's website here: https://algernonpharmaceuticals.com/

 
<< Previous
Bullboard Posts
Next >>